Last reviewed · How we verify
Opioid-Containing
Opioid-containing formulations bind to opioid receptors in the central and peripheral nervous system to reduce pain perception and transmission.
Opioid-containing formulations bind to opioid receptors in the central and peripheral nervous system to reduce pain perception and transmission. Used for Moderate to severe pain (specific indication depends on formulation and approval status).
At a glance
| Generic name | Opioid-Containing |
|---|---|
| Sponsor | OrthoCarolina Research Institute, Inc. |
| Drug class | Opioid analgesic |
| Target | Opioid receptors (mu, delta, kappa) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Opioids work by activating mu, delta, and kappa opioid receptors, which decreases the release of neurotransmitters involved in pain signaling and alters the emotional response to pain. This results in analgesia and can also produce sedation, euphoria, and respiratory depression depending on the dose and formulation.
Approved indications
- Moderate to severe pain (specific indication depends on formulation and strength)
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Respiratory depression
- Dependence/addiction risk
Key clinical trials
- Facilitating Opioid Care Connections (NA)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons (PHASE2)
- Efficacy of Transversus Abdominis Plane Block in Alleviating Acute Appendicitis (NA)
- The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain. (EARLY_PHASE1)
- Comparison of Cumulative Opioid Consumption Between Variable-Rate Feedback Infusion and Fixed-Rate Basal Infusion Modes of Intravenous PCA Following Mixed Surgery (NA)
- Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Opioid-Containing CI brief — competitive landscape report
- Opioid-Containing updates RSS · CI watch RSS
- OrthoCarolina Research Institute, Inc. portfolio CI